Dr Severine Roselli Dayas
Postdoctoral Researcher
School of Biomedical Sciences and Pharmacy (Medical Biochemistry)
- Email:severine.roselli@newcastle.edu.au
- Phone:(02) 4921 5915
Career Summary
Biography
Dr Roselli is a researcher in the School of Biomedical Sciences and Pharmacy. Her research interests focus on understanding the molecular mechanisms involved in the pathophysiology of human diseases such as kidney disease and cancer. Her ultimate research goal is to contribute to the fundamental understanding of these mechanisms in order to identify better treatment strategies for patients. With her combined PhD and post-doctoral experience, she has developed a strong interest in the mechanisms involved in tissue homeostasis, including the interactions between epithelial cells and their environment, and particularly their basement membranes. This applies to all the systems she is interested in; In the kidney glomerulus, the specialized epithelial cells called podocytes together with the glomerular basement membrane are a crucial functional and structural component of the kidney filtration barrier. Podocytes are ‘octopus-like’ mechanosensitive cells composed of a cell body floating in the urinary space and primary processes which divide into actin-rich foot processes, wrapping around the capillary loops and attaching strongly onto the glomerular basement membrane and to each other; thereby forming the ultimate barrier to the passage of blood proteins into the urine. In solid cancers, tumour cells acquire anchorage-independent growth, detach from and invade through the basement membrane in the process of metastasis.
Dr Roselli decided to follow a path towards biomedical research because early on she developed a passion for genetics and hereditary diseases. She completed a PhD in the field of Hereditary kidney disease in France in 2003. During this work, she participated in the identification of a gene (NPHS2) involved in human hereditary nephrotic syndrome, characterized the protein (podocin) and generated a knockout model of the disease.
After her PhD, she received a postdoctoral fellowship from the French Foundation for Medical Research (FRM) to undertake post-doctoral training at the world-renowned Sanford-Burnham Medical Research Institute (La Jolla, USA) in order to gain knowledge in cellular signaling, necessary to fully investigate the function of genes and the mechanisms involved in tissue homeostasis. During her post-doc, she also developed a strong interest in cancer research.
Dr Roselli moved to the University of Newcastle (Australia) in 2007 when she was awarded a Cancer Institute NSW ECR fellowship (2007-2010) to investigate the role of the tetraspanin protein CD151 in breast cancer development and metastasis. At UON, she has also developed her own kidney research, based on the special interest and expertise that she developed in glomerular disease and podocyte biology during her PhD. Her laboratory described the importance of CD151 in the glomerular filtration barrier of the kidney and exploited this model to identify putative biomarkers and drug targets of glomerular disease. At Newcastle, Dr Roselli has established state of the art mouse models for the study of breast cancer and kidney disease.
From April 2012 to February 2015, Dr Roselli worked on several projects with Prof. Hondermarck investigating the value of neurotrophins and their receptors as biomarkers and therapeutic targets in cancer. Since the beginning of 2016, Dr Roselli has teamed up with A/Prof Verrills to study the role of a master regulator of cellular signalling, protein phosphatase 2A (PP2A), in breast cancer. Together they have developed and characterized mouse models of Ppp2r2a (encoding the B55alpha regulatory subunit of PP2A) providing them with a unique tool to investigate the role of B55alpha not only in tumourigenesis but also in development and kidney disease.
Qualifications
- Doctor of Philosophy, University of Paris - France
Keywords
- Podocyte
- breast cancer
- cellular and molecular biology
- genetics
- kidney glomerular disease
- mechanisms of disease
Languages
- English (Fluent)
- French (Mother)
Fields of Research
Code | Description | Percentage |
---|---|---|
321101 | Cancer cell biology | 60 |
320214 | Nephrology and urology | 25 |
320213 | Medical genetics (excl. cancer genetics) | 15 |
Professional Experience
UON Appointment
Title | Organisation / Department |
---|---|
Postdoctoral Researcher | University of Newcastle School of Biomedical Sciences and Pharmacy Australia |
Publications
For publications that are currently unpublished or in-press, details are shown in italics.
Journal article (25 outputs)
Year | Citation | Altmetrics | Link | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
2023 |
Chen Y, Roselli S, Panicker N, Brzozowski JS, Skerrett-Byrne DA, Murray HC, Verrills NM, 'Proteomic and phosphoproteomic characterisation of primary mouse embryonic fibroblasts.', Proteomics, e2300267 (2023) [C1]
|
||||||||||
2020 |
Bond DR, Kahl R, Brzozowski JS, Jankowski H, Naudin C, Pariyar M, et al., 'Tetraspanin CD9 is regulated by MiR-518f-5p and functions in breast cell migration and in vivo tumor growth', Cancers, 12 (2020) [C1]
|
Nova | |||||||||
2020 |
Griffin N, Marsland M, Roselli S, Oldmeadow C, Attia J, Walker MM, et al., 'The receptor tyrosine kinase trka is increased and targetable in HER2-positive breast cancer', Biomolecules, 10 1-13 (2020) [C1] The tyrosine kinase receptor A (NTRK1/TrkA) is increasingly regarded as a therapeutic target in oncology. In breast cancer, TrkA contributes to metastasis but the clinicopathologi... [more] The tyrosine kinase receptor A (NTRK1/TrkA) is increasingly regarded as a therapeutic target in oncology. In breast cancer, TrkA contributes to metastasis but the clinicopathological significance remains unclear. In this study, TrkA expression was assessed via immunohistochemistry of 158 invasive ductal carcinomas (IDC), 158 invasive lobular carcinomas (ILC) and 50 ductal carcinomas in situ (DCIS). TrkA was expressed in cancer epithelial and myoepithelial cells, with higher levels of TrkA positively associated with IDC (39% of cases) (p < 0.0001). Interestingly, TrkA was significantly increased in tumours expressing the human epidermal growth factor receptor-2 (HER2), with expression in 49% of HER2-positive compared to 25% of HER2-negative tumours (p = 0.0027). A panel of breast cancer cells were used to confirm TrkA protein expression, demonstrating higher levels of TrkA (total and phosphorylated) in HER2-positive cell lines. Functional investigations using four different HER2-positive breast cancer cell lines indicated that the Trk tyrosine kinase inhibitor GNF-5837 reduced cell viability, through decreased phospho-TrkA (Tyr490) and downstream AKT (Ser473) activation, but did not display synergy with Herceptin. Overall, these data highlight a relationship between the tyrosine kinase receptors TrkA and HER2 and suggest the potential of TrkA as a novel or adjunct target for HER2-positive breast tumours.
|
Nova | |||||||||
2020 |
Panicker N, Coutman M, Lawlor-O'Neill C, Kahl RGS, Roselli S, Verrills NM, 'Ppp2r2aKnockout Mice Reveal That Protein Phosphatase 2A Regulatory Subunit, PP2A-B55 alpha, Is an Essential Regulator of Neuronal and Epidermal Embryonic Development', FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 8 (2020) [C1]
|
Nova | |||||||||
2018 |
Gao F, Griffin N, Faulkner S, Rowe CW, Williams L, Roselli S, et al., 'The neurotrophic tyrosine kinase receptor TrkA and its ligand NGF are increased in squamous cell carcinomas of the lung', SCIENTIFIC REPORTS, 8 (2018) [C1]
|
Nova | |||||||||
2018 |
Faulkner S, Jobling P, Rowe CW, Rodrigues Oliveira SM, Roselli S, Thorne RF, et al., 'Neurotrophin Receptors TrkA, p75 Neurotrophin receptors are emerging targets in oncology, but their clinicopathologic significance in thyroid cancer is unclear. In this study, the neurotrophin tyrosine receptor k... [more] Neurotrophin receptors are emerging targets in oncology, but their clinicopathologic significance in thyroid cancer is unclear. In this study, the neurotrophin tyrosine receptor kinase TrkA (also called NTRK1), the common neurotrophin receptor p75NTR, and the proneurotrophin receptor sortilin were analyzed with immunohistochemistry in a cohort of thyroid cancers (n = 128) and compared with adenomas and normal thyroid tissues (n = 62). TrkA was detected in 20% of thyroid cancers, compared with none of the benign samples (P = 0.0007). TrkA expression was independent of histologic subtypes but associated with lymph node metastasis (P = 0.0148), suggesting the involvement of TrkA in tumor invasiveness. Nerves in the tumor microenvironment were positive for TrkA. p75NTR was overexpressed in anaplastic thyroid cancers compared with papillary and follicular subtypes (P < 0.0001). Sortilin was overexpressed in thyroid cancers compared with benign thyroid tissues (P < 0.0001). Neurotrophin receptor expression was confirmed in a panel of thyroid cancer cell lines at the mRNA and protein levels. Functional investigations using the anaplastic thyroid cancer cell line CAL-62 found that siRNA against TrkA, p75NTR, and sortilin decreased cell survival and cell migration through decreased SRC and ERK activation. Together, these data reveal TrkA, p75NTR, and sortilin as potential therapeutic targets in thyroid cancer.
|
Nova | |||||||||
2017 |
Watt LF, Panicker N, Mannan A, Copeland B, Kahl RGS, Dun MD, et al., 'Functional importance of PP2A regulatory subunit loss in breast cancer', Breast Cancer Research and Treatment, 166 117-131 (2017) [C1] Purpose: Protein phosphatase 2A (PP2A) is a family of serine/threonine phosphatases that regulate multiple cellular signalling pathways involved in proliferation, survival and apo... [more] Purpose: Protein phosphatase 2A (PP2A) is a family of serine/threonine phosphatases that regulate multiple cellular signalling pathways involved in proliferation, survival and apoptosis. PP2A inhibition occurs in many cancers and is considered a tumour suppressor. Deletion/downregulation of PP2A genes has been observed in breast tumours, but the functional role of PP2A subunit loss in breast cancer has not been investigated. Methods: PP2A subunit expression was examined by immunohistochemistry in human breast tumours, and by qPCR and immunoblotting in breast cancer cell lines. PP2A subunits were inhibited by shRNA, and mutant PP2A genes overexpressed, in MCF10A and MCF7 cells, and growth and signalling in standard and three-dimensional cultures were assessed. Results: Expression of PP2A-Aa, PP2A-Ba and PP2A-B'a subunits was significantly lower in primary human breast tumours and lymph node metastases, compared to normal mammary tissue. PP2A-Aa and the regulatory subunits PP2A-Ba, -Bd and -B'¿ were also reduced in breast cancer cell lines compared to normal mammary epithelial cells. Functionally, shRNA-mediated knockdown of PP2A-Ba, -B'a and -B'¿, but not PP2A-Aa, induced hyper-proliferation and large multilobular acini in MCF10A 3D cultures, characterised by activation of ERK. Expression of a breast cancer-associated PP2A-A mutant, PP2A-Aa-E64G, which inhibits binding of regulatory subunits to the PP2A core, induced a similar hyper-proliferative phenotype. Knockdown of PP2A-Ba also induced hyper-proliferation in MCF7 breast cancer cells. Conclusion: These results suggest that loss of specific PP2A regulatory subunits is functionally important in breast tumourigenesis, and support strategies to enhance PP2A activity as a therapeutic approach in breast cancer.
|
Nova | |||||||||
2017 |
Naudin C, Smith B, Bond DR, Dun MD, Scott RJ, Ashman LK, et al., 'Characterization of the early molecular changes in the glomeruli of Cd151 -/- mice highlights induction of mindin and MMP-10.', Scientific Reports, 7 15987-15987 (2017) [C1]
|
Nova | |||||||||
2016 |
Faulkner S, Roselli S, Demont Y, Pundavela J, Choquet G, Leissner P, et al., 'ProNGF is a potential diagnostic biomarker for thyroid cancer', Oncotarget, 7 28488-28497 (2016) [C1] The precursor for nerve growth factor (proNGF) is expressed in some cancers but its clinicopathological significance is unclear. The present study aimed to define the clinicopatho... [more] The precursor for nerve growth factor (proNGF) is expressed in some cancers but its clinicopathological significance is unclear. The present study aimed to define the clinicopathological significance of proNGF in thyroid cancer. ProNGF expression was analysed by immunohistochemistry in two cohorts of cancer versus benign tumors (adenoma) and normal thyroid tissues. In the first cohort (40 thyroid cancers, 40 thyroid adenomas and 80 normal thyroid tissues), proNGF was found overexpressed in cancers compared to adenomas and normal samples (p<0.0001). The area under the receiver-operating characteristic (ROC) curve was 0.84 (95% CI 0.75-0.93, p<0.0001) for cancers versus adenomas, and 0.99 (95% CI 0.98-1.00, p<0.0001) for cancers versus normal tissues. ProNGF overexpression was confirmed in a second cohort (127 cancers of various histological types and 55 normal thyroid tissues) and using a different antibody (p<0.0001). ProNGF staining intensity was highest in papillary carcinomas compared to other histological types (p<0.0001) and there was no significant association with age, gender, tumor size, stage and lymph node status. In conclusion, proNGF is increased in thyroid cancer and should be considered as a new potential diagnostic biomarker.
|
Nova | |||||||||
2015 |
Roselli S, Pundavela J, Demont Y, Faulkner S, Keene S, Attia J, et al., 'Sortilin is associated with breast cancer aggressiveness and contributes to tumor cell adhesion and invasion', Oncotarget, 6 10473-10486 (2015) [C1] The neuronal membrane protein sortilin has been reported in a few cancer cell lines, but its expression and impact in human tumors is unclear. In this study, sortilin was analyzed... [more] The neuronal membrane protein sortilin has been reported in a few cancer cell lines, but its expression and impact in human tumors is unclear. In this study, sortilin was analyzed by immunohistochemistry in a series of 318 clinically annotated breast cancers and 53 normal breast tissues. Sortilin was detected in epithelial cells, with increased levels in cancers, as compared to normal tissues (p = 0.0088). It was found in 79% of invasive ductal carcinomas and 54% of invasive lobular carcinomas (p < 0.0001). There was an association between sortilin expression and lymph node involvement (p = 0.0093), suggesting a relationship with metastatic potential. In cell culture, sortilin levels were higher in cancer cell lines compared to non-tumorigenic breast epithelial cells and siRNA knockdown of sortilin inhibited cancer cell adhesion, while proliferation and apoptosis were not affected. Breast cancer cell migration and invasion were also inhibited by sortilin knockdown, with a decrease in focal adhesion kinase and SRC phosphorylation. In conclusion, sortilin participates in breast tumor aggressiveness and may constitute a new therapeutic target against tumor cell invasion.
|
Nova | |||||||||
2015 |
Jobling P, Pundavela J, Oliveira SMR, Roselli S, Walker MM, Hondermarck H, 'Nerve-Cancer Cell Cross-talk: A Novel Promoter of Tumor Progression', CANCER RESEARCH, 75 1777-1781 (2015) [C1]
|
Nova | |||||||||
2015 |
Pundavela J, Roselli S, Faulkner S, Attia J, Scott RJ, Thorne RF, et al., 'Nerve fibers infiltrate the tumor microenvironment and are associated with nerve growth factor production and lymph node invasion in breast cancer', Molecular Oncology, 9 1626-1635 (2015) [C1]
|
Nova | |||||||||
2014 |
Pundavela J, Demont Y, Jobling P, Lincz LF, Roselli S, Thorne RF, et al., 'ProNGF correlates with Gleason score and is a potential driver of nerve infiltration in prostate cancer', American Journal of Pathology, 184 3156-3162 (2014) [C1] Nerve infiltration is essential to prostate cancer progression, but the mechanism by which nerves are attracted to prostate tumors remains unknown. We report that the precursor of... [more] Nerve infiltration is essential to prostate cancer progression, but the mechanism by which nerves are attracted to prostate tumors remains unknown. We report that the precursor of nerve growth factor (proNGF) is overexpressed in prostate cancer and involved in the ability of prostate cancer cells to induce axonogenesis. A series of 120 prostate cancer and benign prostate hyperplasia (BPH) samples were analyzed by IHC for proNGF. ProNGF was mainly localized in the cytoplasm of epithelial cells, with marked expression in cancer compared with BPH. Importantly, the proNGF level positively correlated with the Gleason score (n = 104, tB = 0.51). A higher level of proNGF was observed in tumors with a Gleason score of =8 compared with a Gleason score of 7 and 6 (P < 0.001). In vitro, proNGF was detected in LNCaP, DU145, and PC-3 prostate cancer cells and BPH-1 cells but not in RWPE-1 immortalized nontumorigenic prostate epithelial cells or primary normal prostate epithelial cells. Co-culture of PC12 neuronal-like cells or 50B11 neurons with PC-3 cells resulted in neurite outgrowth in neuronal cells that was inhibited by blocking antibodies against proNGF, indicating that prostate cancer cells can induce axonogenesis via secretion of proNGF. These data reveal that ProNGF is a biomarker associated with high-risk prostate cancers and a potential driver of infiltration by nerves.
|
Nova | |||||||||
2014 |
Roselli S, Kahl RGS, Copeland BT, Naylor MJ, Weidenhofer J, Muller WJ, Ashman LK, 'Deletion of Cd151 reduces mammary tumorigenesis in the MMTV/PyMT mouse model', BMC Cancer, 14 (2014) [C1] Background: Tetraspanins are transmembrane proteins that serve as scaffolds for multiprotein complexes containing, for example, integrins, growth factor receptors and matrix metal... [more] Background: Tetraspanins are transmembrane proteins that serve as scaffolds for multiprotein complexes containing, for example, integrins, growth factor receptors and matrix metalloproteases, and modify their functions in cell adhesion, migration and transmembrane signaling. CD151 is part of the tetraspanin family and it forms tight complexes with ß1 and ß4 integrins, both of which have been shown to be required for tumorigenesis and/or metastasis in transgenic mouse models of breast cancer. High levels of the tetraspanin CD151 have been linked to poor patient outcome in several human cancers including breast cancer. In addition, CD151 has been implicated as a promoter of tumor angiogenesis and metastasis in various model systems.Methods: Here we investigated the effect of Cd151 deletion on mammary tumorigenesis by crossing Cd151-deficient mice with a spontaneously metastasising transgenic model of breast cancer induced by the polyoma middle T antigen (PyMT) driven by the murine mammary tumor virus promoter (MMTV).Results: Cd151 deletion did not affect the normal development and differentiation of the mammary gland. While there was a trend towards delayed tumor onset in Cd151 -/- PyMT mice compared to Cd151 +/+ PyMT littermate controls, this result was only approaching significance (Log-rank test P-value =0.0536). Interestingly, Cd151 deletion resulted in significantly reduced numbers and size of primary tumors but did not appear to affect the number or size of metastases in the MMTV/PyMT mice. Intriguingly, no differences in the expression of markers of cell proliferation, apoptosis and blood vessel density was observed in the primary tumors.Conclusion: The findings from this study provide additional evidence that CD151 acts to enhance tumor formation initiated by a range of oncogenes and strongly support its relevance as a potential therapeutic target to delay breast cancer progression. © 2014 Roselli et al.; licensee BioMed Central Ltd.
|
Nova | |||||||||
2014 |
Bond DB, Brzozowski J, Skelding KA, Roselli SR, Weidenhofer J, 'Use of tetraspanins CD151 and CD9 as biomarkers for breast cancer', Breast Cancer Management, 3 123-126 (2014) [C3]
|
Nova | |||||||||
2010 |
Roselli SM, Wallez Y, Wang L, Vervoort V, Pasquale EB, 'The SH2 domain protein Shep1 regulates the in vivo signaling function of the scaffolding protein Cas', Cellular Signalling, 22 1745-1752 (2010) [C1]
|
||||||||||
2008 |
Baleato R, Guthrie PL, Gubler M-C, Ashman LK, Roselli SM, 'Deletion of Cd151 results in a strain-dependent glomerular disease due to severe alterations of the glomerular basement membrane', American Journal of Pathology, 173 927-937 (2008) [C1]
|
Nova | |||||||||
Show 22 more journal articles |
Conference (28 outputs)
Year | Citation | Altmetrics | Link | |||||
---|---|---|---|---|---|---|---|---|
2022 | Perl A, Koetsier J, Roselli S, Panicker N, Verrills N, Green K, 'PP2A-B55 alpha dephosphorylates desmoplakin's C-terminus to regulate cell adhesion', JOURNAL OF INVESTIGATIVE DERMATOLOGY (2022) | |||||||
2021 |
Afrin F, Mannan A, Woldu A, Duchatel R, Douglas AM, Jiang CC, et al., 'Cannabidiol and low-THC cannabis extracts for the treatment of acute myeloid leukaemia', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2021)
|
|||||||
2021 |
Chen Y, Murray H, AlMazi J, Brozozwski J, Mannan A, Panicker N, et al., 'Proteogenomics identifies oncogenic signalling pathways regulated by the tumour suppressor, PP2A-B55 alpha', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2021)
|
|||||||
2015 |
Watt LF, Panicker N, Copeland B, Kahl RGS, Dun MD, Young B, et al., 'PP2A a novel biomarker and therapeutic target for poor outcome breast cancer', Proceedings of the Lowy Cancer Conference, Sydney (2015) [E3]
|
|||||||
2015 |
Pundavela J, Roselli S, Demont Y, Faulkner S, Attia J, Keene S, et al., 'The neuronal protein sortilin is expressed in aggressive breast cancers and participates in tumor cell growth and invasion', CANCER RESEARCH, San Antonio, TX (2015) [E3]
|
|||||||
2015 |
Oliveira S, Roselli S, Hondermarck H, Jobling P, 'Nerve fibers infiltrate ovarian cancer and may be related to tumor aggressiveness', JOURNAL OF NEUROCHEMISTRY, Cairns, AUSTRALIA (2015) [E3]
|
|||||||
2015 |
Naudin C, Weidenhofer J, Roselli S, Keely S, 'Induction of Mindin is Associated with Pathological Changes in the Kidney of Cd151(-/-) Mice', FASEB JOURNAL (2015) [E3]
|
|||||||
2015 |
Faulkner S, Roselli S, Demont Y, Choquet G, Leissner P, Oldmeadow C, et al., 'ProNGF AS A NEW BIOMARKER IN THYROID CANCER', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2015) [E3]
|
|||||||
2014 |
Faulkner S, Roselli S, Thorne RF, Scarlett CJ, Walker MM, Hondermarck H, 'PRONGF AND SORTILIN EXPRESSION AND FUNCTION IN PANCREATIC CANCER', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
|
|||||||
2014 |
Oliveira SMR, Roselli S, Hondermarck H, Jobling P, 'PERIPHERAL NERVES ARE ASSOCIATED WITH SOME OVARIAN TUMOURS', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
|
|||||||
2012 |
Roselli SM, Moscato PA, Scott R, Hondermarck H, 'Breast cancer proteomics: Integrating the data with genomics and histology towards clinical applications', 18th Proteomics Symposium. Delegate Handbook, Lorne, Vic (2012) [E3]
|
|||||||
2011 |
Naudin C, Weidenhofer JC, Scott R, Ashman LK, Roselli SM, 'Induction of mindin expression is associated with glomerular basement membrane damage in Cd151(-/-) mice', Nephrology, Adelaide, SA (2011) [E3]
|
|||||||
Show 25 more conferences |
Grants and Funding
Summary
Number of grants | 18 |
---|---|
Total funding | $2,266,611 |
Click on a grant title below to expand the full details for that specific grant.
20221 grants / $605,670
A dual approach to activate a tumour suppressor for breast cancer therapy$605,670
Funding body: NHMRC (National Health & Medical Research Council)
Funding body | NHMRC (National Health & Medical Research Council) |
---|---|
Project Team | Associate Professor Nikki Verrills, Doctor Severine Roselli Dayas, Associate Professor Jonathan Morris |
Scheme | Ideas Grants |
Role | Investigator |
Funding Start | 2022 |
Funding Finish | 2024 |
GNo | G2100530 |
Type Of Funding | C1100 - Aust Competitive - NHMRC |
Category | 1100 |
UON | Y |
20211 grants / $51,126
HMRI Researcher Bridging Fund$51,126
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Doctor Severine Roselli Dayas |
Scheme | Research Grant |
Role | Lead |
Funding Start | 2021 |
Funding Finish | 2021 |
GNo | G2100444 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
20191 grants / $4,500
Kyratec PCR machine$4,500
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Associate Professor Nikki Verrills, Doctor Severine Roselli Dayas, Professor Matt Dun |
Scheme | Early and Mid-Career Equipment Grant |
Role | Investigator |
Funding Start | 2019 |
Funding Finish | 2019 |
GNo | G1900111 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
20182 grants / $29,141
A new approach for treating therapy resistant breast cancer$25,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Doctor Severine Roselli Dayas, Associate Professor Nikki Verrills, Doctor Nick Zdenkowski, Dr James Lynam |
Scheme | Project Grant |
Role | Lead |
Funding Start | 2018 |
Funding Finish | 2018 |
GNo | G1801453 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
Jennie Thomas Medical Research Travel Grant - Nikita Panicker$4,141
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Miss Nikita Panicker, Associate Professor Nikki Verrills, Doctor Severine Roselli Dayas, Professor Matt Dun |
Scheme | Jennie Thomas Medical Research Travel Grant |
Role | Investigator |
Funding Start | 2018 |
Funding Finish | 2018 |
GNo | G1800024 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
20171 grants / $24,000
Targeting a tumour suppressor for new cancer therapies $24,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Associate Professor Nikki Verrills, Professor Matt Dun, Doctor Severine Roselli Dayas |
Scheme | Project Grant |
Role | Investigator |
Funding Start | 2017 |
Funding Finish | 2018 |
GNo | G1700588 |
Type Of Funding | C3300 – Aust Philanthropy |
Category | 3300 |
UON | Y |
20141 grants / $20,000
Prostate Cancer: A new protein for improving diagnosis, prognosis and treatment$20,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Doctor Severine Roselli Dayas, Professor Hubert Hondermarck |
Scheme | Project Grant |
Role | Lead |
Funding Start | 2014 |
Funding Finish | 2014 |
GNo | G1401520 |
Type Of Funding | Grant - Aust Non Government |
Category | 3AFG |
UON | Y |
20131 grants / $24,596
Ultra-Low Temperature Cryogenic Freezer$24,596
Funding body: NHMRC (National Health & Medical Research Council)
Funding body | NHMRC (National Health & Medical Research Council) |
---|---|
Project Team | Doctor Jude Weidenhofer, Doctor Rick Thorne, Associate Professor Kathryn Skelding, Associate Professor Nikki Verrills, Professor Pradeep Tanwar, Associate Professor Phillip Dickson, Professor Murray Cairns, Professor Hubert Hondermarck, Professor Xu Dong Zhang, Associate Professor Estelle Sontag, Doctor Chen Chen Jiang, Prof LIZ Milward, Doctor Jean-Marie Sontag, Associate Professor Paul Tooney, Doctor Severine Roselli Dayas, Professor Matt Dun, Professor Chris Dayas, Doctor Lin Kooi Ong, Professor Dirk Van Helden, Mr Ben Copeland, Doctor Gabrielle Briggs, Emeritus Professor Leonie Ashman, Emeritus Professor John Rostas |
Scheme | Equipment Grant |
Role | Investigator |
Funding Start | 2013 |
Funding Finish | 2013 |
GNo | G1201189 |
Type Of Funding | Other Public Sector - Commonwealth |
Category | 2OPC |
UON | Y |
20121 grants / $34,000
Microscopic illumination system for advanced fluorescent protein technology$34,000
Funding body: NHMRC (National Health & Medical Research Council)
Funding body | NHMRC (National Health & Medical Research Council) |
---|---|
Project Team | Doctor Rick Thorne, Professor Xu Dong Zhang, Professor Murray Cairns, Associate Professor Nikki Verrills, Doctor Charles De Bock, Doctor Jude Weidenhofer, Doctor Severine Roselli Dayas, Associate Professor Kathryn Skelding, Emeritus Professor Leonie Ashman, Professor Hubert Hondermarck |
Scheme | Equipment Grant |
Role | Investigator |
Funding Start | 2012 |
Funding Finish | 2012 |
GNo | G1100983 |
Type Of Funding | Other Public Sector - Commonwealth |
Category | 2OPC |
UON | Y |
20112 grants / $35,000
Investigation of the function of CD151 in the glomerular filtration barrier and identification of genetic modifiers of glomerular diseases$25,000
Funding body: University of Newcastle
Funding body | University of Newcastle |
---|---|
Project Team | Doctor Severine Roselli Dayas, Doctor Jude Weidenhofer, Emeritus Professor Leonie Ashman |
Scheme | Near Miss Grant |
Role | Lead |
Funding Start | 2011 |
Funding Finish | 2011 |
GNo | G1001053 |
Type Of Funding | Internal |
Category | INTE |
UON | Y |
IMPLEN NanoPhotometer pearl$10,000
Funding body: NHMRC (National Health & Medical Research Council)
Funding body | NHMRC (National Health & Medical Research Council) |
---|---|
Project Team | Professor Murray Cairns, Associate Professor Paul Tooney, Professor Alan Brichta, Emeritus Professor John Rostas, Emeritus Professor Patricia Michie, Conjoint Professor Keith Jones, Prof ULLI Schall, Associate Professor Phillip Dickson, Professor Rohan Walker, Doctor Rick Thorne, Professor Chris Dayas, Associate Professor Nikki Verrills, Doctor Janet Bristow, Doctor Severine Roselli Dayas, Associate Professor Kathryn Skelding, Doctor Jude Weidenhofer, Prof LIZ Milward, Doctor Charles De Bock, Doctor Julie Merriman-Jones, Doctor Jing Qin Wu, Doctor Bing Liu, Doctor Dan Johnstone, Ms Belinda Goldie, Doctor Natalie Beveridge |
Scheme | Equipment Grant |
Role | Investigator |
Funding Start | 2011 |
Funding Finish | 2011 |
GNo | G1100030 |
Type Of Funding | Other Public Sector - Commonwealth |
Category | 2OPC |
UON | Y |
20101 grants / $34,000
ABI 7500 Real Time PCR System $34,000
Funding body: NHMRC (National Health & Medical Research Council)
20094 grants / $775,000
Electron Microscopes for Nanometer-scale Imaging/Microanalysis in the Materials, Biological, Physical, Engineering and Chemical Sciences$650,000
Funding body: ARC (Australian Research Council)
Electron Microscopes for Nanometer-scale Imaging/Microanalysis in the Materials, Biological, Physical, Engineering and Chemical Sciences$70,000
Funding body: ARC (Australian Research Council)
FACSAria$30,000
Funding body: NHMRC (National Health & Medical Research Council)
Funding body | NHMRC (National Health & Medical Research Council) |
---|---|
Project Team | Doctor Rick Thorne, Doctor Severine Roselli Dayas, Professor Xu Dong Zhang, Dr Charles De Bock, Conjoint Professor Peter Hersey, Professor Gordon Burns |
Scheme | Equipment Grant |
Role | Investigator |
Funding Start | 2009 |
Funding Finish | 2009 |
GNo | G0189846 |
Type Of Funding | Other Public Sector - Commonwealth |
Category | 2OPC |
UON | Y |
Identification of genetic modifiers of kidney disease$25,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Doctor Severine Roselli Dayas, Emeritus Professor Leonie Ashman, Professor Rodney Scott |
Scheme | Project Grant |
Role | Lead |
Funding Start | 2009 |
Funding Finish | 2009 |
GNo | G0189793 |
Type Of Funding | Contract - Aust Non Government |
Category | 3AFC |
UON | Y |
20081 grants / $75,000
Role of tetraspanin proteins in human breast and prostate cancer$75,000
Funding body: Hunter Medical Research Institute
Funding body | Hunter Medical Research Institute |
---|---|
Project Team | Emeritus Professor Leonie Ashman, Doctor Severine Roselli Dayas |
Scheme | Mary Minto Sawyer Grant |
Role | Investigator |
Funding Start | 2008 |
Funding Finish | 2010 |
GNo | G0188187 |
Type Of Funding | Grant - Aust Non Government |
Category | 3AFG |
UON | Y |
20071 grants / $554,578
Murine models to determine the role of the tetraspanin CD151 in epithelial tumour initiation and progression$554,578
Funding body: Cancer Institute NSW
Funding body | Cancer Institute NSW |
---|---|
Project Team | Doctor Severine Roselli Dayas |
Scheme | Career Development Fellowship |
Role | Lead |
Funding Start | 2007 |
Funding Finish | 2009 |
GNo | G0186974 |
Type Of Funding | Grant - Aust Non Government |
Category | 3AFG |
UON | Y |
Research Supervision
Number of supervisions
Current Supervision
Commenced | Level of Study | Research Title | Program | Supervisor Type |
---|---|---|---|---|
2022 | PhD | Activation Of A Tumour Suppressor In Triple Negative Breast Cancer | PhD (Medical Biochemistry), College of Health, Medicine and Wellbeing, The University of Newcastle | Co-Supervisor |
Past Supervision
Year | Level of Study | Research Title | Program | Supervisor Type |
---|---|---|---|---|
2022 | PhD | Functional Role of Protein Phosphatase 2A and its Regulatory Subunit B55a in Development and Breast Cancer | PhD (Medical Biochemistry), College of Health, Medicine and Wellbeing, The University of Newcastle | Co-Supervisor |
2018 | PhD | ProNGF, NGF and their Receptors in Tumour Innervation and Progression: a Study in Breast and Thyroid Cancers | PhD (Medical Biochemistry), College of Health, Medicine and Wellbeing, The University of Newcastle | Co-Supervisor |
2018 | PhD | The Nerve-Cancer Connection in Ovarian Cancer | PhD (Human Physiology), College of Health, Medicine and Wellbeing, The University of Newcastle | Co-Supervisor |
2015 | PhD | The Tetraspanin CD151's Role in the Kidney and Mapping of Genetic Modifiers of Glomerular Diseases | PhD (Medical Biochemistry), College of Health, Medicine and Wellbeing, The University of Newcastle | Co-Supervisor |
2013 | PhD | Tetraspanins as Biomarkers and Causative Proteins in Prostate Cancer | PhD (Medical Biochemistry), College of Health, Medicine and Wellbeing, The University of Newcastle | Co-Supervisor |
2012 | PhD | The Role of Protein Phosphatase 2A as a Tumour Suppressor in Breast Cancer | PhD (Medical Biochemistry), College of Health, Medicine and Wellbeing, The University of Newcastle | Co-Supervisor |
Research Projects
Verrills Laboratory 2012 -
Grants
A dual approach to activate a tumour suppressor for breast cancer therapy
Funding body: NHMRC (National Health & Medical Research Council)
Funding body | NHMRC (National Health & Medical Research Council) |
---|---|
Project Team | Doctor Severine Roselli Dayas, Associate Professor Jonathan Morris, Associate Professor Nikki Verrills |
Scheme | Ideas Grants |
Targeting DNA-PK in acute myeloid leukaemia
Funding body: NHMRC (National Health & Medical Research Council)
Funding body | NHMRC (National Health & Medical Research Council) |
---|---|
Project Team | Associate Professor Nikki Verrills, Associate Professor Anoop Enjeti |
Scheme | Ideas Grants |
Publications
Roberts KG, Smith AM, McDougall FK, Carpenter HC, Horan MP, Neviani P, et al., 'Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers', Cancer Research, 70 5438-5447 (2010) [C1]
Smith AM, Dun MD, Lee EM, Harrison C, Kahl R, Flanagan H, et al., 'Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors', Oncotarget, 7 47465-47478 (2016) [C1]
Murray HC, Dun MD, Verrills NM, 'Harnessing the power of proteomics for identification of oncogenic, druggable signalling pathways in cancer', Expert Opinion on Drug Discovery, 12 431-447 (2017) [C1]
Watt LF, Panicker N, Mannan A, Copeland B, Kahl RGS, Dun MD, et al., 'Functional importance of PP2A regulatory subunit loss in breast cancer', Breast Cancer Research and Treatment, 166 117-131 (2017) [C1]
Dun MD, Mannan A, Rigby CJ, Butler S, Toop HD, Beck D, et al., 'Shwachman Bodian Diamond syndrome (SBDS) protein is a direct inhibitor of protein phosphatase 2A (PP2A) activity and overexpressed in acute myeloid leukaemia', Leukemia, 34 3393-3397 (2020) [C1]
Panicker N, Coutman M, Lawlor-O'Neill C, Kahl RGS, Roselli S, Verrills NM, 'Ppp2r2aKnockout Mice Reveal That Protein Phosphatase 2A Regulatory Subunit, PP2A-B55 alpha, Is an Essential Regulator of Neuronal and Epidermal Embryonic Development', FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 8 (2020) [C1]
Murray HC, Enjeti AK, Kahl RGS, Flanagan HM, Sillar J, Skerrett-Byrne DA, et al., 'Quantitative phosphoproteomics uncovers synergy between DNA-PK and FLT3 inhibitors in acute myeloid leukaemia', LEUKEMIA, 35 1782-1787 (2021)
Students
Program | Research Title |
---|---|
PhD College of Health, Medicine and Wellbeing |
Multiomic Characterisation of Cellular Signalling Regulated by PP2A-B55a in Breast Cancer and Development |
Collaborators
Name | Organisation |
---|---|
Doctor Heather Constance Murray | University of Newcastle |
Doctor Nikita Panicker | University of Newcastle |
Miss Charley Louise Lawlor-O'Neill | University of Newcastle |
Doctor Lauren Frances Watt | University of Newcastle |
Miss Kasey Erin Miller | University of Newcastle |
Mr Joshua Stephen Sidney Brzozowski | University of Newcastle |
Miss Yanfang Chen | University of Newcastle |
Doctor Severine Roselli Melanie Dayas | University of Newcastle |
Edit
Dr Severine Roselli Dayas
Position
Postdoctoral Researcher
School of Biomedical Sciences and Pharmacy
College of Health, Medicine and Wellbeing
Focus area
Medical Biochemistry
Contact Details
severine.roselli@newcastle.edu.au | |
Phone | (02) 4921 5915 |
Fax | (02) 4921 6903 |
Office
Room | LS3-37 |
---|---|
Building | Life Sciences |
Location | Callaghan University Drive Callaghan, NSW 2308 Australia |